Jeffrey A Cohen

Oct 22, 2024 | neurologylive.com | Daniel Ontaneda |Jeffrey A Cohen

In the last 30 years, no subspecialty in neurology has seen greater advancements in treatment than multiple sclerosis (MS). With more than 20 disease-modifying therapies (DMTs) approved and more in the pipeline, we are now able to essentially freeze the disease in its course and reduce disability progression, when treatment is started early.

Apr 14, 2024 | journals.sagepub.com | Marisa McGinley |Jeffrey A Cohen

Cite articleIf you have citation software installed, you can download article citation data to the citation manager of your choiceSelect your citation manager software:Share optionsShare this articleShare with emailEMAIL ARTICLE LINKShare on social mediaShare access to this articleSharing links are not relevant where the article is open access and not available if you do not have a subscription. For more information view the Sage Journals article sharingpage.

Mar 1, 2024 | neurologylive.com | Jeffrey A Cohen

WATCH TIME: 4 minutes"In the long term extension, the effects on relapses in MRI lesion activity increased and reached the same level as those patients that had been on ozanimod, previously.

Oct 25, 2023 | neurologylive.com | Jeffrey A Cohen |Sarah Anderson |Alicyn Magruder |Matt Hoffman

October 25, 2023Alicyn Magruder, PharmD, BCACP, MSCS, offers insight into the pharmacist's role in patient education on biosimilars for MS, and the group discusses the potential need for a long-term monitoring system. [WATCH TIME: 10 minutes]WATCH TIME: 10 minutesThe treatment paradigm for multiple sclerosis (MS) has come a long way since the early years of ABCR agents, with a therapeutic arsenal of disease-modifying therapies now numbering in the 20s.

Oct 23, 2023 | neurologylive.com | Jeffrey A Cohen |Sarah Anderson |Alicyn Magruder |Matt Hoffman

WATCH TIME: 9 minutesThe treatment paradigm for multiple sclerosis (MS) has come a long way since the early years of ABCR agents, with a therapeutic arsenal of disease-modifying therapies now numbering in the 20s. Yet, with all of the change that advances in pharmaceutical development have brought, there are still novel approaches being introduced—and perhaps the biggest recent introduction is biosimilars.